Works matching Cutaneous T-cell lymphoma (CTCL)

Results: 1294
    1
    2
    3
    4
    5
    6
    7
    8

    JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).

    Published in:
    Cancers, 2021, v. 13, n. 2, p. 280, doi. 10.3390/cancers13020280
    By:
    • Vadivel, Chella Krishna;
    • Gluud, Maria;
    • Torres-Rusillo, Sara;
    • Boding, Lasse;
    • Willerslev-Olsen, Andreas;
    • Buus, Terkild B.;
    • Nielsen, Tea Kirkegaard;
    • Persson, Jenny L.;
    • Bonefeld, Charlotte M.;
    • Geisler, Carsten;
    • Krejsgaard, Thorbjorn;
    • Fuglsang, Anja T.;
    • Odum, Niels;
    • Woetmann, Anders
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21

    miR-155 expression in Primary Cutaneous T-Cell Lymphomas (CTCL).

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2017, v. 31, n. 1, p. e27, doi. 10.1111/jdv.13597
    By:
    • Fava, P.;
    • Bergallo, M.;
    • Astrua, C.;
    • Brizio, M.;
    • Galliano, I.;
    • Montanari, P.;
    • Daprà, V.;
    • Novelli, M.;
    • Savoia, P.;
    • Quaglino, P.;
    • Fierro, M.T.
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29
    30

    FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 286, doi. 10.1002/hon.96_2630
    By:
    • Horwitz, S.M.;
    • Scarisbrick, J.;
    • Prince, H.M.;
    • Whittaker, S.;
    • Duvic, M.;
    • Kim, Y.H.;
    • Quaglino, P.;
    • Zinzani, P.L.;
    • Bechter, O.;
    • Eradat, H.;
    • Pinter‐Brown, L.;
    • Akilov, O.;
    • Geskin, L.;
    • Sanches, J.;
    • Ortiz‐Romero, P.;
    • Lisano, J.;
    • Brown, L.;
    • Palanca‐Wessels, M.C.;
    • Gautam, A.;
    • Bunn, V.
    Publication type:
    Article
    31
    32
    33

    FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 286, doi. 10.1002/hon.96_2630
    By:
    • Horwitz, S.M.;
    • Scarisbrick, J.;
    • Prince, H.M.;
    • Whittaker, S.;
    • Duvic, M.;
    • Kim, Y.H.;
    • Quaglino, P.;
    • Zinzani, P.L.;
    • Bechter, O.;
    • Eradat, H.;
    • Pinter‐Brown, L.;
    • Akilov, O.;
    • Geskin, L.;
    • Sanches, J.;
    • Ortiz‐Romero, P.;
    • Lisano, J.;
    • Brown, L.;
    • Palanca‐Wessels, M.C.;
    • Gautam, A.;
    • Bunn, V.
    Publication type:
    Article
    34
    35
    36

    RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY.

    Published in:
    Hematological Oncology, 2017, v. 35, p. 245, doi. 10.1002/hon.2438_109
    By:
    • Horwitz, S.;
    • Whittaker, S.;
    • Duvic, M.;
    • Dummer, R.;
    • Kim, Y.H.;
    • Scarisbrick, J.;
    • Quaglino, P.;
    • Zinzani, P.;
    • Wolter, P.;
    • Eradat, H.;
    • Sanches, J.;
    • Ortiz ‐ Romero, P.;
    • Akilov, O.;
    • Trotman, J.;
    • Taylor, K.;
    • Dalle, S.;
    • Weichenthal, M.;
    • Walewski, J.;
    • Fisher, D.;
    • Wang, Y.
    Publication type:
    Article
    37
    38

    PH 1 TRIAL EVALUATING MRG-106, A MICRORNA-155 INHIBITOR, ADMINISTERED BY INTRATUMORAL, SUBCUTANEOUS, OR INTRAVENOUS DELIVERY IN CUTANEOUS T-CELL LYMPHOMA (CTCL) PATIENTS.

    Published in:
    Hematological Oncology, 2017, v. 35, p. 275, doi. 10.1002/hon.2438_149
    By:
    • Querfeld, C.;
    • Foss, F.M.;
    • Porcu, P.;
    • Kim, Y.H.;
    • Pacheco, T.;
    • Haverkos, B.;
    • Halwani, A.S.;
    • DeSimone, J.;
    • William, B.;
    • Pinter ‐ Brown, L.;
    • Seto, A.;
    • Ruckman, J.;
    • Landry, M.;
    • Jackson, A.L.;
    • Dickinson, B.;
    • Sanseverino, M.;
    • Rodman, D.;
    • Rubin, P.;
    • Marshall, W.S.
    Publication type:
    Article
    39

    Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results.

    Published in:
    Hematological Oncology, 2017, v. 35, p. 48, doi. 10.1002/hon.2437_31
    By:
    • Bagot, M.;
    • Porcu, P.;
    • Ram ‐ Wolff, C.;
    • Khodadoust, M.;
    • Basem, W.;
    • Battistella, M.;
    • Marie ‐ Cardine, A.;
    • Vermeer, M.;
    • Mathieu, S.;
    • Whittaker, S.;
    • Duvic, M.;
    • Bensussan, A.;
    • Paturel, C.;
    • Bonnafous, C.;
    • Thonnart, N.;
    • Widemann, A.;
    • Bonin, C.;
    • Sicard, H.;
    • Paiva, C.;
    • Pilz, K.
    Publication type:
    Article
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50